KCNH1
KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Overview
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarisation, reaches a steady-state level and do not inactivate. The activation kinetics depend on the prepulse potential and external divalent cation concentration. With negative prepulses, the current activation is delayed and slowed down several fold, whereas more positive prepulses speed up activation.
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.33, clinical 0.76).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
- 1 · What it is
KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
- 2 · What goes wrong in cancer
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarisation, reaches a steady-state level and do not inactivate.
- 3 · How drugs use it
No product in this corpus aims at KCNH1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:6250 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95259 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000143473 (association with cancer (MONDO_0004992) 0.54; (GraphQL API, CC0))
Biology
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarisation, reaches a steady-state level and do not inactivate. The activation kinetics depend on the prepulse potential and external divalent cation concentration. With negative prepulses, the current activation is delayed and slowed down several fold, whereas more positive prepulses speed up activation. The time course of activation is biphasic with a fast and a slowly activating current component. Activates at more positive membrane potentials and exhibit a steeper activation curve. Channel properties are modulated by subunit assembly. Location: Cell membrane; Nucleus inner membrane; Cell projection, dendrite; Cell projection, axon (UniProt). Locus 1q32.2 (HGNC).
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.76. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"KCNH1" OR ABSTRACT:"KCNH1" OR TITLE:"potassium voltage-gated channel subfamily H member 1" OR ABSTRACT:"potassium voltage-gated channel subfamily H member 1" OR TITLE:"Voltage-gated delayed rectifier potassium channel KCNH1" OR ABSTRACT:"Voltage-gated delayed rectifier potassium channel KCNH1" OR TITLE:"Kv10.1" OR ABSTRACT:"Kv10.1" OR TITLE:"eag" OR ABSTRACT:"eag" OR TITLE:"h-eag" OR ABSTRACT:"h-eag") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNH1, not a curated reading list.